BioMarin Pharmaceutical Inc. Free Cash Flow 2008–2025
BioMarin Pharmaceutical Inc. reported $724.96M of free cash flow for fiscal 2025. That was 48.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +2604.4%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $724.96M | +48.7% |
| FY 2024 | $487.42M | +679.0% |
| FY 2023 | $62.57M | +13.9% |
| FY 2022 | $54.94M | -73.7% |
| FY 2021 | $208.96M | +821.9% |
| FY 2020 | $-28.95M | +70.1% |
| FY 2019 | $-96.76M | +22.2% |
| FY 2018 | $-124.41M | +40.2% |
| FY 2017 | $-207.98M | +44.7% |
| FY 2016 | $-376.22M | +15.9% |
| FY 2015 | $-447.15M | -138.5% |
| FY 2014 | $-187.48M | -50.2% |
| FY 2013 | $-124.83M | -363.0% |
| FY 2012 | $-26.96M | +50.8% |
| FY 2011 | $-54.80M | -78.4% |
| FY 2010 | $-30.71M | -1384.5% |
| FY 2009 | $-2.07M | +96.8% |
| FY 2008 | $-65.54M | — |
Source: BioMarin Pharmaceutical Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BMRN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
BioMarin Pharmaceutical Inc. reported $724.96M of free cash flow for fiscal 2025. That was 48.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +2604.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for BioMarin Pharmaceutical Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBioMarin Pharmaceutical Inc. — frequently asked questions
What is BioMarin Pharmaceutical Inc.'s free cash flow?
BioMarin Pharmaceutical Inc. (BMRN) reported free cash flow of $724.96M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from BioMarin Pharmaceutical Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.